Access to injectable biologic medications by medicare beneficiaries: geographic distribution of US dermatologist prescribers. (3rd April 2019)

• Record Type: Journal Article
• Authors: Feng, Hao; Cohen, Jeffrey M.; Neimann, Andrea L.
• Is Part Of: Journal of dermatological treatment. Volume 30:Number 3(2019)
• Page Start: 237
• Page End: 239
• Publication Date: 2019-04-03
• Subjects: Biologics -- medical dermatology -- health services research; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2018.1508819
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Purpose: Injectable biologics (IB) are important in dermatology and we sought to examine the distribution of US IB-prescribing dermatologists. Materials and methods: We used Centers for Medicare and Medicaid Services Medicare Provider Utilization and Payment Data: Part D for 2013–2015. The density of dermatologists who prescribe IB (etanercept, adalimumab, ustekinumab, secukinumab) in each US county, represented as number of dermatologists per 100, 000 Medicare Part D beneficiaries, was calculated. Results: 2, 992 dermatologists (26.3% of dermatologists) prescribed IB in this study. The national density of IB-prescribing dermatologists was 7.22. Only 778 counties (24.8%) have at least one IB-prescribing dermatologist. The densities of IB-prescribing dermatologists in metropolitan counties were 8.07–8.12. The densities of IB-prescribing dermatologists were 4.55 and 6.51 for urban populations of greater than 20, 000 people adjacent and non-adjacent to metropolitan areas, respectively. Urban counties with populations between 2, 500–19, 999 and adjacent to a metropolitan area had a density of 2.03 and urban counties with the same population and not adjacent to a metropolitan area had a density of 2.84. Completely rural or urban counties with populations under 2, 500 people had densities between 2.31–2.35. Conclusions: There are disparities in the availability of IB-prescribing dermatologists across urban-rural geographic settings in the US.